Skip to main content
Log in

Pharmacological Options for the Treatment of Tourette’s Disorder

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Tourette’s disorder is a neuropsychiatric disorder characterised clinically by motor and vocal tics, which may be associated to conductual disorders such as obsessive-compulsive disorder (OCD) and attention-deficit hyperactivity disorder (ADHD). Although the neurochemistry of Tourette’s disorder is not well known, there are some effective therapies for tics, OCD and ADHD. However, these are not devoid of adverse effects.

Tics only require treatment when they interfere with the functioning of the patient. If therapy is needed, monotherapy at the minimal effective dose is desirable, but some patients may require two or more drugs. The most frequently used drugs for tics are antipsychotics (mainly pimozide and haloperidol) and clonidine. The potential usefulness of atypical antipsychotic drugs (risperidone, olanzapine, clozapine, ziprasidone) and other dopaminergic drugs (fluphenazine, sulpiride, tiapride, metoclopramide, piquindone, tetrabenazine), clonazepam, calcium channel antagonists, botulinum toxin, dopamine agonists, selegiline, and other drugs is discussed.

The drugs of choice for OCD in patients with Tourette’s disorder are the selective serotonin reuptake inhibitors (SSRIs), although the tricyclic antidepressant clomiplamine, which inhibits both serotonin and noradrenaline uptake, has also been found to be useful.

ADHD can be treated with some psychostimulants, mainly methylphenidate, although these drugs must be used with caution. Other potentially useful drugs for the treatment of ADHD in patients with Tourette’s disorder are clonidine, guanfacine, selegiline, some tricyclic antidepressants, sertraline, pimozide and clonazepam.

Finally, the potential value of some nonpharmacological therapies (hypnotherapy, biofeedback, conductual therapies, electroconvulsive therapy, acupuncture and surgery) is briefly reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Robertson MM. The Gilles de la Tourette syndrome: the current status. Br J Psychiatry 1989; 154: 147–69

    Article  PubMed  CAS  Google Scholar 

  2. Singer HS, Walkup JT. Tourette syndrome and other tic disorders. Diagnosis, pathophysiology, and treatment. Medicine (Baltimore) 1991; 70: 15–32

    CAS  Google Scholar 

  3. Suchowerski O. Gilles de la Tourette syndrome. Can J Neurol Sci 1994; 21: 48–52

    Google Scholar 

  4. Lajonchere C, Nortz M, Finger S. Gilles de la Tourette and the discovery of Tourette syndrome. Arch Neurol 1996; 53: 567–74

    Article  PubMed  CAS  Google Scholar 

  5. Jiménez-Jiménez FJ, García-Ruiz PJ, Zurdo M. Síndrome de Tourette. In: Jiménez-Jiménez FJ, Luquin MR, Molina JA, editors. Tratado de los trastornos del movimiento. Madrid: IM&C 1998: 931–64

    Google Scholar 

  6. The Tourette Syndrome Classification Study Group. Definitions and classification of tic disorders. Arch Neurol 1993; 50: 1013–6

    Article  Google Scholar 

  7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington DC: American Psychiatry Press, 1994

    Google Scholar 

  8. Cardoso F, Veado CC, de Oliveira JT. A Brazilian cohort of patients with Tourette’s syndrome. J Neurol Neurosurg Psychiatry 1996; 60: 209–12

    Article  PubMed  CAS  Google Scholar 

  9. Tanner CM, Goldman SM. Epidemiology or Tourette’s syndrome. Neurol Clin 1997; 15: 395–402

    Article  PubMed  CAS  Google Scholar 

  10. Pauls DL, Leckman JF. The inheritance of Gilles de la Tourette’s syndrome and associated behaviors: evidence for autosomal dominant transmission. N Engl J Med 1986; 315: 993–7

    Article  PubMed  CAS  Google Scholar 

  11. Price RA, Pauls DL, Kruger SD, et al. Family data support a dominant major gene for Tourette syndrome. Psychiatry Res 1988; 24: 251–61

    Article  PubMed  CAS  Google Scholar 

  12. Pauls DL, Pakstis AJ, Kurlan R, et al. Segregation and linkage analyses of Tourette’s syndrome and related disorders. J Am Acad Child Adolec Psychiatry 1990; 29: 195–203

    Article  CAS  Google Scholar 

  13. Robertson MM, Gourdie A. Tourette syndrome in a large British pedigree. Associated psychopathology, severity, and potential for linkage analysis. Br J Psychiatry 1990; 156: 515–21

    Article  PubMed  CAS  Google Scholar 

  14. Curtis D, Robertson MM, Gurling HM. Autosomal dominant gene transmission in a large kindred with Gilles de la Tourette syndrome. Br J Psychiatry 1992; 160: 845–9

    Article  PubMed  CAS  Google Scholar 

  15. Eapen V, Pauls DL, Robertson MM. Evidence for autosomal dominant transmission in Tourette’s syndrome. United Kingdom cohort study. Evidence for autosomal dominant transmission in Tourette’s syndrome. United Kingdom cohort study. Br J Psychiatry 1993; 162: 593–6

    Article  PubMed  CAS  Google Scholar 

  16. Kurlan R, Behr J, Medved L, et al. Transient tic disorder and the spectrum of Tourette’s syndrome. Arch Neurol 1988; 45: 1200–1

    Article  PubMed  CAS  Google Scholar 

  17. Van de Wetering BJM, Heutink P. The genetics of the Gilles de la Tourette syndrome. A review. J Lab Clin Med 1993; 121: 638–45

    PubMed  Google Scholar 

  18. Kurlan R, Bher J, Medved L, et al. Familial Tourette’s syndrome: report of a large pedigree and potential for linkage analysis. Neurology 1986; 36: 772–6

    Article  PubMed  CAS  Google Scholar 

  19. Kurlan R, Eapen V, Stern J, et al. Bilinear transmission in Tourette’s syndrome families. Neurology 1994; 44: 2336–42

    Article  PubMed  CAS  Google Scholar 

  20. McMahon WM, van der Wetering BJ, Filloux F, et al. Bilineal transmission and phenotypic variation of Tourette’s disorder in a large population. J Am Acad Child Adolesc Psychiatry 1996; 35: 672–80

    Article  PubMed  CAS  Google Scholar 

  21. Comings ED, Comings BG, Knell E. Hypothesis: homozygosity in Tourette syndrome. Am J Med Genet 1989; 34: 413–21

    Article  PubMed  CAS  Google Scholar 

  22. Walkup JT, LaBuda MC, Singer HS, et al. Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance. Am J Hum Genet 1996; 59: 684–93

    PubMed  CAS  Google Scholar 

  23. Bressman S, Greene P. Treatment of hyperkinetic movement disorders. Neurol Clin 1990; 8: 51–75

    PubMed  CAS  Google Scholar 

  24. Scahill L, Chappel PB, King RA, et al. Pharmacologic treatment of tic disorders. Child Adolesc Psychiatry Clin N Am 2000; 9: 99–117

    CAS  Google Scholar 

  25. Regeur L, Werdelin L, Pakkenberg H, et al. Pharmacological treatment of Gilles de la Tourette’s syndrome. CNS Drugs 1994; 2: 191–8

    Article  Google Scholar 

  26. Seignot MJN. Un cas de maladie des tics de Gilles de la Tourette gueri par le R-1625. Ann Med Psychol 1961; 119: 578–9

    Google Scholar 

  27. Caprini G, Melotti V. Un grave syndrome ticcosa guerita con haloperidol. Riv Sper Freniatr Med Leg Ailen Ment 1961; 85: 191–6

    Google Scholar 

  28. Lucas AR. Gilles de la Tourette’s disease in children: treatment with haloperidol. Am J Psychiatry 1967; 124: 243–5

    PubMed  CAS  Google Scholar 

  29. Shapiro AK, Shapiro E. Treatment of Gilles de la Tourette’s syndrome with haloperidol. Br J Psychiatry 1968; 114: 345–50

    Article  PubMed  CAS  Google Scholar 

  30. Boris M. Gilles de la Tourette’s syndrome: remission with haloperidol [letter]. JAMA 1968; 205: 648–9

    Article  PubMed  CAS  Google Scholar 

  31. Ford CV, Gottlieb F. An objective evaluation of haloperidol in Gilles de la Tourette’s syndrome. Dis Nerv Syst 1969; 30: 328–32

    PubMed  CAS  Google Scholar 

  32. Craven EM. Gilles de la Tourette syndrome treated with haloperidol [letter]. JAMA 1969; 210: 134

    Article  PubMed  CAS  Google Scholar 

  33. Bixby Jr EW. Haloperidol for the Gilles de la tourette syndrome [letter]. JAMA 1970; 211: 663

    Article  PubMed  Google Scholar 

  34. Shapiro AK, Shapiro E, Bruun RD, et al. Treatment of Tourette’s syndrome with haloperidol. Review of 34 cases. Am J Psychiatry 1973; 28: 92–7

    CAS  Google Scholar 

  35. Perera HV. Two cases of Gilles de la Tourette’s syndrome treated with haloperidol. Br J Psychiatry 1975; 127: 324–6

    Article  PubMed  CAS  Google Scholar 

  36. Bruun RD, Shapiro AK, Shapiro E, et al. A follow-up of 78 patients with Gilles de la Tourette’s syndrome. Am J Psychiatry 1976; 133: 944–7

    PubMed  CAS  Google Scholar 

  37. Clarke DJ, Ford R. Treatment of refractory Tourette syndrome with haloperidol decanoate. Acta Psychiatr Scand 1988; 77: 495–6

    Article  PubMed  CAS  Google Scholar 

  38. Mikkelsen EJ, Detlor J, Cohen DJ. School avoidance and social phobia triggered by haloperidol in patients with Tourette’s disorder. Am J Psychiatry 1981; 138: 1572–6

    PubMed  CAS  Google Scholar 

  39. Troung DD, Bressman S, Shale H, et al. Clonazepam, haloperidol, and clonidine in tic disorders. South Med J 1988; 81: 1103–5

    Article  PubMed  CAS  Google Scholar 

  40. Silva RR, Muñoz DM, Daniel W, et al. Causes of haloperidol discontinuation in patients with Tourette’s disorder: management and alternatives. J Clin Psychiatry 1996; 57: 129–35

    PubMed  CAS  Google Scholar 

  41. Robertson MM, Stern JS. Gilles de la Tourette syndrome: symptomatic treatment based on evidence. Eur Child Adolesc Psychiatry 2000; 9 Suppl. 1:1 60–75

    Article  Google Scholar 

  42. Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette’s syndrome. Am J Psychiatry 1978; 135: 585–7

    PubMed  CAS  Google Scholar 

  43. Shapiro AK, Shapiro E, Einsenkarft GJ. Treatment of Gilles de la Tourette syndrome with pimozide. Am J Psychiatry 1983; 140: 1183–6

    PubMed  CAS  Google Scholar 

  44. Shapiro AK, Shapiro E. Controlled study of pimozide vs. placebo in Tourette’s syndrome. J Am Acad Child Psychiatry 1984; 23: 161–73

    Article  PubMed  CAS  Google Scholar 

  45. Regeur L, Pakkenberg B, Fog R, et al. Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette’s syndrome. J Neurol Neurosurg Psychiatry 1986; 49: 791–5

    Article  PubMed  CAS  Google Scholar 

  46. Shapiro AK, Shapiro E, Fulop G. Pimozide treatment of tic and Tourette disorders. Pediatrics 1987; 79: 1032–9

    PubMed  CAS  Google Scholar 

  47. Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 1989; 46: 722–30

    Article  PubMed  CAS  Google Scholar 

  48. Sandor P, Musisi S, Moldofsky H, et al. Tourette syndrome: a follow-up study. J Clin Psychopharmacol 1990; 10: 197–9

    Article  PubMed  CAS  Google Scholar 

  49. Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette’s disorder. Am J Psychiatry 1997; 154: 1057–62

    PubMed  CAS  Google Scholar 

  50. Fulop G, Phillips RA, Shapiro AK, et al. ECG changes during haloperidol and pimozide treatment of Tourette’s disorder. Am J Psychiatry 1987; 144: 673–5

    PubMed  CAS  Google Scholar 

  51. Sallee FR, Sethuraman G, Rock CM. Effects of pimozide on cognition in children with Tourette’s syndrome: interaction with comorbid attention deficit hyperactivity disorder. Acta Psychiatr Scand 1994; 90: 4–9

    Article  PubMed  CAS  Google Scholar 

  52. Tourette Syndrome Study Group. Short-term versus longer term pimozide therapy in Tourette’s syndrome: a preliminary study. Neurology 1999; 52: 874–7

    Article  Google Scholar 

  53. Van der Linden C, Bruggeman R, van Woerkom TC. Serotonin-dopamine antagonist and Gilles de la Tourette’s syndrome: an open pilot dose-titration study with risperidone. Mov Disord 1994; 9: 687–8

    Article  PubMed  Google Scholar 

  54. Stamenkovic M, Aschauer H, Kasper S. Risperidone for Tourette’s syndrome [letter]. Lancet 1994; 344: 1577–8

    Article  PubMed  CAS  Google Scholar 

  55. Giakas WJ. Risperidone treatment for Tourette’s disorder patient with comorbid obsessive-compulsive disorder [letter]. Am J Psychiatry 1995; 152: 1097–8

    PubMed  CAS  Google Scholar 

  56. Shulman LM, Singer C, Weiner WJ. Risperidone in Gilles de la Tourette syndrome [letter]. Neurology 1995; 45: 1419

    Article  PubMed  CAS  Google Scholar 

  57. Lombroso PJ, Scahill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a prelimininary report. J Am Acad Child Adolesc Psychiatry 1995; 34: 1147–52

    Article  PubMed  CAS  Google Scholar 

  58. Bruun RD, Budman CL. Risperidone as a treatment for Tourette’s syndrome. J Clin Psychiatry 1996; 57: 29–31

    PubMed  CAS  Google Scholar 

  59. Bhadrinath BR. Olanzapine in Tourette syndrome [letter]. Br J Psychiatry 1998; 172: 366

    Article  PubMed  CAS  Google Scholar 

  60. Stamenkovic M, Schindler SD, Aschauer HN, et al. Effective open-label treatment of Tourette’s disorder with olanzapine. Int Clin Psychopharmacol 2000; 15: 23–8

    Article  PubMed  CAS  Google Scholar 

  61. Onofrj M, Paci C, D’Andramatteo G, et al. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol 2000; 247: 443–6

    Article  PubMed  CAS  Google Scholar 

  62. Caine ED, Polinsky RJ, Kartzinel R, et al. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979; 136: 317–20

    PubMed  CAS  Google Scholar 

  63. Schmider J, Hoff P. Clozapine in Tourette’s syndrome [letter]. J Clin Psychopharmacol 1998; 18: 88–9

    Article  PubMed  CAS  Google Scholar 

  64. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000; 39: 292–9

    Article  PubMed  CAS  Google Scholar 

  65. Singer HS, Gammon K, Quaskey S. Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci 1986; 12: 71–4

    Article  CAS  Google Scholar 

  66. Goetz CG, Tanner CM, Klawans HL. Fluphenazine and multifocal tic disorders. Arch Neurol 1984; 41: 271–2

    Article  PubMed  CAS  Google Scholar 

  67. Yvonneau M, Bezard P. Sur un cas de maladie des tics bloquee par le sulphide. Étude psycho-biologique. Encéphale 1970; 59: 439–59

    PubMed  CAS  Google Scholar 

  68. Trillet M, Moreau T, Dalery J, et al. Traitement de la maladie de Gilles de la Tourette par l’amisulpride. Presse Méd 1990; 19: 175

    PubMed  CAS  Google Scholar 

  69. Robertson MM, Schnieden V, Lees AJ. Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol 1990; 13: 229–35

    Article  PubMed  CAS  Google Scholar 

  70. Eggers CH, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatr Neurol Sci 1988; 237: 223–9

    Article  CAS  Google Scholar 

  71. Smirnov AI. O primenenii metoklopramida (tserukala) pri sindrome Turetta. Zh Nevropatol Psikhiatr 1989; 89: 105–8

    PubMed  Google Scholar 

  72. Uhr SB, Pruitt B, Berger PA, et al. Improvement of symptoms in Tourette syndrome by piquindone, a novel dopamine-2 receptor antagonist. Int Clin Psychopharmacol 1986; 1: 216–20

    Article  PubMed  CAS  Google Scholar 

  73. Jankovic J, Glaze DG, Frost Jr JD. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette’s syndrome. Neurology 1984; 34: 688–92

    Article  PubMed  CAS  Google Scholar 

  74. Vieregge P. Tetrabenazine in the treatment of senile vocal tics [letter]. J Neurol 1987; 235: 126–7

    Article  PubMed  CAS  Google Scholar 

  75. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988; 38: 391–4

    Article  PubMed  CAS  Google Scholar 

  76. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48: 358–62

    Article  PubMed  CAS  Google Scholar 

  77. Cohen DJ, Young JG, Nathanson JA, et al. Clonidine in Tourette’s syndrome. Lancet 1979; 2: 551–3

    Article  PubMed  CAS  Google Scholar 

  78. Cohen DJ, Detlor J, Young JG, et al. Clonidine ameloriates Gilles de la Tourette syndrome. Arch Gen Psychiatry 1980; 37: 1350–7

    Article  PubMed  CAS  Google Scholar 

  79. Leckman JF, Cohen DJ, Detlor J, et al. Clonidine in the treatment of Tourette syndrome: a review of the data. Adv Neurol 1982; 35: 391–401

    PubMed  CAS  Google Scholar 

  80. Leckman JF, Detlor J, Harcherick DF, et al. Short- and long-term treatment of Tourette’s syndrome with clonidine: a clinical perspective. Neurology 1985; 35: 343–51

    Article  PubMed  CAS  Google Scholar 

  81. Mesulam MM, Petersen RC. Treatment of Gilles de la Tourette’s syndrome: eight-year, practice based experience in a predominantly adult population. Neurology 1987; 37: 1828–33

    Article  PubMed  CAS  Google Scholar 

  82. Leckman JF, Hardin MT, Riddle MA, et al. Clonidine treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 1991; 48: 324–8

    Article  PubMed  CAS  Google Scholar 

  83. Lichter DG, Jackson LA. Predictors of clonidine response in Tourette syndrome: implications and inferences. J Child Neurol 1996; 11: 93–7

    Article  PubMed  CAS  Google Scholar 

  84. Gancher S, Conant-Norville D, Angell R. Treatment of Tourette’s syndrome with transdermal clonidine: a pilot study. J Neuropsychiatry Clin Neurosci 1990; 2: 66–9

    PubMed  CAS  Google Scholar 

  85. Goetz CG, Tanner CM, Wilson RS, et al. Clonidine and Gilles de la Tourette’s syndrome: double-blind study using objective rating methods. Ann Neurol 1987; 21: 307–10

    Article  PubMed  CAS  Google Scholar 

  86. Leckman JF, Ort S, Caruso KA, et al. Rebound phenomena in Tourette’s syndrome after abrupt withdrawal of clonidine: behavioral, cardiovascular and neurochemical effects. Arch Gen Psychiatry 1986; 43: 1168–71

    Article  PubMed  CAS  Google Scholar 

  87. Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette’s syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995; 34: 1140–6

    Article  PubMed  CAS  Google Scholar 

  88. Gonce M, Barbeau A. Seven cases of Gilles de la Tourette’s syndrome: a partial relief with clonazepam: a pilot study. Can J Neurol Sci 1977; 4: 279–83

    PubMed  CAS  Google Scholar 

  89. Goetz CG. Clonidine and clonazepam in Tourettes syndrome. Adv Neurol 1992; 58: 245–51

    PubMed  CAS  Google Scholar 

  90. Steingard RJ, Goldberg M, Lee D, et al. Adjuntive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. J Am Acad Child Adolesc Psychiatry 1994; 33: 394–9

    Article  PubMed  CAS  Google Scholar 

  91. Kurlan R. Tourette syndrome. Treatment of tics. Neurol Clin 1997; 15: 403–9

    Article  PubMed  CAS  Google Scholar 

  92. Gillman MA, Sandyk R. Clonazepam-induced Tourette syndrome in a subject with hyperkplexia [letter]. Postgrad Med J 1987; 63: 311–2

    Article  PubMed  CAS  Google Scholar 

  93. Jenner P, Pratt JA, Marsden CD. Mechanism of action of clonazepam in relation to effects of GABA and 5-HT. Adv Neurol 1986; 43: 629–43

    PubMed  CAS  Google Scholar 

  94. Chung Hwang E, Van Woert MH. Antimyoclonic action of clonazepam: the role of serotonin. Eur J Pharmacol 1979; 23: 31–40

    Article  Google Scholar 

  95. Krishnamoorthy PV. Evidence for synergism between the antimyoclonic action of hydroxytryptophan and clonazepam in rats. Eur J Pharmacol 1988; 149: 331–5

    Article  PubMed  Google Scholar 

  96. Tenn CC, Niles LP. Central type benzodiazepines receptors mediate the antidopaminergic effect of clonazepam and melatonin in 6-hydroxydopamine lesioned rats: involvement of a GABAergic mechanism. J Pharmacol Exp Ther 1995; 274: 84–9

    PubMed  CAS  Google Scholar 

  97. Tenn CC, Niles LP. Mechanism underlying the antidopaminergic effect of clonazepam and melatonin in striatum. Neuropharmacology 1997; 36: 1659–63

    Article  PubMed  CAS  Google Scholar 

  98. Goldstein JA. Nifedipine treatment of Tourettes syndrome [letter]. J Clin Psychiatry 1984; 45: 360

    PubMed  CAS  Google Scholar 

  99. Berg R. A case of Tourette’s syndrome treated with nifedipine [letter]. Acta Psychiatr Scand 1985; 72: 400–1

    Article  PubMed  CAS  Google Scholar 

  100. Walsh TL, Lavenstein B, Licamele W, et al. Calcium antagonists in the treatment of Tourettes syndrome [letter]. Am J Psychiatry 1986; 143: 1467–8

    PubMed  CAS  Google Scholar 

  101. Jiménez-Jiménez FJ, García-Ruiz PJ, García de Yébenes J, et al. Nicardipine improves motor tics. Eur J Neurol 1997; 4: 498–501

    Article  Google Scholar 

  102. Micheli F, Gatto M, Lekhuniec E, et al. Treatment of Tourettes syndrome with calcium antagonists. Clin Neuropharmacol 1990; 13: 77–83

    Article  PubMed  CAS  Google Scholar 

  103. Martí-Masso JF, Carrera N, De la Puente E. Posible parkinsonismo por cinarizina. Med Clin Barc 1985; 85: 614–6

    PubMed  Google Scholar 

  104. Cortelli P, Santucci M, Righetti F, et al. Neuroendocrinological effect of an antidopaminergic effect of flunarizine. Acta Neurol Scand 1988; 77: 289–92

    Article  PubMed  CAS  Google Scholar 

  105. Giménez-Roldán S, Mateo D. Cinnarizine induced parkinsonism: susceptibility related to aging and essential tremor. Clin Neuropharmacol 1989; 14: 156–64

    Article  Google Scholar 

  106. García-Ruiz PJ, García de Yébenes J, Jiménez-Jiménez FJ, et al. Parkinsonism associated with calcium channel blockers: a prospective follow-up study. Clin Neuropharmacol 1992; 15: 19–26

    Article  PubMed  Google Scholar 

  107. García-Ruiz PJ, Mena MA, Peñafiel N, et al. Cinnarizine induced parkinsonism in primates. Clin Neuropharmacol 1992; 15: 152–4

    Article  PubMed  Google Scholar 

  108. García-Albea E, Jiménez-Jiménez FJ, Ayuso-Peralta L, et al. Parkinsonism unmasked by verapamil. Clin Neuropharmacol 1993; 16: 263–5

    Article  PubMed  Google Scholar 

  109. García-Ruiz PJ. Calcium channel blockers and movement disorders. Eur J Clin Res 1997; 9: 9–20

    Google Scholar 

  110. De Vries DJ, Beart PM. Competitive inhibition of H3 spiperone binding to D2 dopamine receptors in striatal homogenates by organic calcium channel antagonists and polyvalent cations. Eur J Pharmacol 1985; 106: 133–9

    Article  Google Scholar 

  111. Pileblad E, Carlsson A. The Ca antagonist nimodipine decreases and the Ca agonist BAY K 8644 increases catecholamines synthesis in mouse brain. Neuropharmacology 1987; 26: 101–6

    Article  PubMed  CAS  Google Scholar 

  112. Mena MA, García de Yébenes MJ, Tabernero C, et al. Effect of calcium antagonists on the dopamine system. Clin Neuropharmacol 1995; 18: 410–26

    Article  PubMed  CAS  Google Scholar 

  113. Gelb D, Lowenstein D, Aminoff M. Controlled trial of Botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 1989; 39: 80–4

    Article  PubMed  CAS  Google Scholar 

  114. Blackie JD, Lees AJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1990; 53: 640–3

    Article  PubMed  CAS  Google Scholar 

  115. Greene P, Kang U, Fahn S, et al. Double-blind placebo controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990; 40: 1213–8

    Article  PubMed  CAS  Google Scholar 

  116. Koman LA, Mooney JF, Smith BP, et al. Management of spasticity in cerebral palsy with botulinum A toxin: report of a preliminary, randomized, double blind trial. J Pediatr Orthop 1994; 14: 299–303

    Article  PubMed  CAS  Google Scholar 

  117. García-Ruiz PJ, Pascual-Pascual I, Sanchez-Bernardos V. Progressive response to botulinum toxin in cerebral palsy. Eur J Neurol 2000; 7: 191–3

    Article  PubMed  Google Scholar 

  118. Jankovic J. Botulinum toxin in the treatment of dystonic tics. MovDisord 1994; 9: 347–9

    Article  CAS  Google Scholar 

  119. Awaad Y. Tics in Tourette syndrome: new treatment options. J Child Neurol 1999; 14: 316–9

    Article  PubMed  CAS  Google Scholar 

  120. Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol 2000; 57: 1190–3

    Article  PubMed  CAS  Google Scholar 

  121. Scott BL, Jankovic J, Donovan DT. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette’s syndrome. Mov Disord 1996; 11:431–3

    Article  PubMed  CAS  Google Scholar 

  122. Salloway S, Stewart CF, Israeli L, et al. Botulinum toxin for refractory vocal tics. Mov Disord 1996; 11: 746–8

    Article  PubMed  CAS  Google Scholar 

  123. Trimble MR, Whurr R, Brookes G, et al. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord 1998; 13: 617–9

    Article  PubMed  CAS  Google Scholar 

  124. Feinberg M, Carroll BJ. Effects of dopamine agonists and antagonists in Tourette’s disease. Arch Gen Psychiatry 1979; 36: 979–85

    Article  PubMed  CAS  Google Scholar 

  125. Lipinski JF, Sallee FR, Jackson C, et al. Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov Disord 1997; 12: 402–7

    Article  PubMed  CAS  Google Scholar 

  126. Gilbert DL, Sheturaman G, Sine L, et al. Tourettes syndrome improvement with pergolide in a randomized double blind, crossover trial. Neurology 2000; 28: 1310–5

    Article  Google Scholar 

  127. Goetz CG, Stebbins GT, Thelen JA. Talipexole and adult Gilles de la Tourette’s syndrome: double-blind, placebo-controlled clinical trial. Mov Disord 1994; 9: 315–7

    Article  PubMed  CAS  Google Scholar 

  128. Dursun SM, Burke JG, Reveley MA. Buspirone tratment of Tourette’s syndrome [letter]. Lancet 1995; 345: 1366–7

    Article  PubMed  CAS  Google Scholar 

  129. Jankovic J. Deprenyl in attention deficit associated with Tourette’s syndrome. Arch Neurol 1993; 50: 286–8

    Article  PubMed  CAS  Google Scholar 

  130. Feigin A, Kurlan R, McDermott MP, et al. A controlled trial of deprenyl in children with Tourette’s syndrome and attention deficit hyperactivity disorder. Neurology 1996; 46: 965–8

    Article  PubMed  CAS  Google Scholar 

  131. Toren P, Laor N, Cohen DJ, et al. Ondansetron treatment in patients with Tourette’s syndrome. Int Clin Psychopharmacol 1999; 14: 373–6

    Article  PubMed  CAS  Google Scholar 

  132. Bonnier C, Nassogne MC, Evrard P. Ketanserine treatment of Tourette’s syndrome in children [letter]. Am J Psychiatry 1999; 156: 1122–3

    PubMed  CAS  Google Scholar 

  133. Cath DC, Gijsman HJ, Schoemaker RC, et al. The effect of m-CPP on tics and obsessive-compulsive phenomena in Gilles de la Tourette syndrome. Psychopharmacology (Berl) 1999; 144: 137–43

    Article  CAS  Google Scholar 

  134. Sanberg PR, Fogelson HM, Manderscheid PZ, et al. Nicotine gum and haloperidol in Tourette’s syndrome [letter]. Lancet 1988; I: 592

    Article  Google Scholar 

  135. McConville BJ, Fogelson MH, Norman AB, et al. Nicotine potentiation of haloperidol in reducing tic frequency in Tourette’s disorder [letter]. Am J Psychiatry 1991; 148: 793–4

    PubMed  CAS  Google Scholar 

  136. McConville BJ, Sanberg PR, Fogelson MH, et al. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette’s disorder. Biol Psychiatry 1992; 31: 832–40

    Article  PubMed  CAS  Google Scholar 

  137. Silver AA, Sanberg PR. Transdermal nicotine patch and potentiation of haloperidol in Tourette’s syndrome [letter]. Lancet 1993; 342: 182

    Article  PubMed  CAS  Google Scholar 

  138. Dursun SM, Reveley MA, Bird R, et al. Long-lasting improvement of Tourette’s syndrome with transdermal nicotine. Lancet 1994; 344: 1577

    Article  PubMed  CAS  Google Scholar 

  139. Silver AA, Shytle RD, Philipp MK, et al. Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 1996; 35: 1631–6

    Article  PubMed  CAS  Google Scholar 

  140. Dursun SM, Reveley MA. Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette’s syndrome: an open study. Psychol Med 1997; 27: 483–7

    Article  PubMed  CAS  Google Scholar 

  141. Sanberg PR, Shytle RD, Silver AA. Treatment of Tourette’s syndrome with mecamylamine [letter]. Lancet 1998; 352: 705–6

    Article  PubMed  CAS  Google Scholar 

  142. Polinsky RJ, Ebert MH, Caine ED, et al. Cholinergic treatment in the Tourette syndrome. N Engl J Med 1980; 302: 1310

    Article  PubMed  CAS  Google Scholar 

  143. Barbeau A. Cholinergic treatment in the Tourette syndrome. N Engl J Med 1980; 302: 1310–1

    Article  PubMed  CAS  Google Scholar 

  144. Stahl SM, Berger PA. Physostigmine in Tourette’s syndrome: evidence for cholinergic underactivity. Am J Psychiatry 1981; 138: 240–2

    Article  PubMed  CAS  Google Scholar 

  145. Tanner CM, Goetz CG, Klawans HL. Cholinergic mechanisms in Tourette’s syndrome. Neurology 1982; 32: 1315–7

    Article  PubMed  CAS  Google Scholar 

  146. Rosenberg GS, Davis KL. Precursors of acetylcholine: considerations underlying their use in Tourette’s syndrome. Adv Neurol 1982; 35: 407–12

    PubMed  CAS  Google Scholar 

  147. Moldofsky H, Sandor P. Lecithin in the treatment of Gilles de la Tourette’s syndrome. Am J Psychiatry 1983; 140: 1627–9

    PubMed  CAS  Google Scholar 

  148. Sandyk R. The effects of naloxone in Tourette’s syndrome [letter]. Ann Neurol 1985; 18: 367–8

    Article  PubMed  CAS  Google Scholar 

  149. Kurlan R, Majumdar L, Deeley C, et al. A controlled trial of propoxyphene and naltrexone in patients with Tourette’s syndrome. Ann Neurol 1991; 30; 19–23

    Article  PubMed  CAS  Google Scholar 

  150. Erenberg G, Lederman RJ. Naltrexone and Tourette’s syndrome [letter]. Ann Neurol 1992; 31: 574

    Article  PubMed  CAS  Google Scholar 

  151. Meuldijk R, Colon EJ. Methadone treatment of Tourette’s disorder [letter]. Am J Psychiatry 1992; 149: 139–40

    PubMed  CAS  Google Scholar 

  152. Shapira NA, McConville BJ, Pagnucco ML, et al. Novel use of tramadol hydrochloride in the treatment of Tourette’s syndrome [letter]. J Clin Psychiatry 1997; 58: 175

    Article  Google Scholar 

  153. Gadoth N, Gordon CR, Streifler J. Naloxone in Gilles de la Tourette syndrome [letter]. Ann Neurol 1987; 21: 415

    Article  PubMed  CAS  Google Scholar 

  154. Sandyk R, Awerbuch G. Marijuana and Tourette’s syndrome [letter]. J Clin Psychopharmacol 1988; 8: 444–5

    Article  PubMed  CAS  Google Scholar 

  155. Hemming M, Yellowlees PM. Effective treatment or Tourette’s syndrome with marijuana. J Clin Psychopharmacol 1993; 7: 389–91

    CAS  Google Scholar 

  156. Müller-Vahl KR, Kolbe H, Dengler R. Gilles de la Tourette syndrome. Einfluss von nikotin, alkohol un marihuana auf die klinische symptomatik. Nervenartz 1997; 68: 985–9

    Article  Google Scholar 

  157. Müller-Vahl KR, Kolbe H, Schneider U, et al. Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand 1998; 98: 503–6

    Article  Google Scholar 

  158. Müller-Vahl KR, Schneider U, Kolbe H, et al. Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol [letter]. J Clin Psychiatry 1999; 156: 495

    Google Scholar 

  159. Peterson BS, Leckman JF, Scahill L, et al. Steroid hormones and Tourette’s syndrome: early experience with antiandrogen therapy. J Clin Psychopharmacol 1994; 14: 131–5

    Article  PubMed  CAS  Google Scholar 

  160. Sandyk R, Bamford CR. Estrogen as adjuvant treatment of Tourette syndrome [letter]. Pediatr Neurol 1987; 3: 122

    Article  PubMed  CAS  Google Scholar 

  161. Izmir M, Dursun SM. Cyproterone acetate treatment of Tourette’s syndrome [letter]. Can J Psychiatry 1999; 44: 710–1

    PubMed  CAS  Google Scholar 

  162. Leckman JF, Scahill L. Possible exacerbation of tics by androgenic steroids [letter]. N Engl J Med 1990; 322: 1674

    PubMed  CAS  Google Scholar 

  163. Peterson BS, Zhang H, Anderson GM, et al. A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette’s syndrome. J Clin Psychopharmacol 1998; 18: 324–31

    Article  PubMed  CAS  Google Scholar 

  164. Kerbeshian J, Burd L. Differential responsiveness to lithium in patients with Tourette’s disorder. Neurosci Biobehav Rev 1988; 12: 247–50

    Article  PubMed  CAS  Google Scholar 

  165. Erickson Jr HM, Goggin JE, Messiha FS. Comparison of lithium and haloperidol therapy in Gilles de la Tourette syndrome. Adv Exp Med Biol 1977; 90: 197–205

    Article  PubMed  Google Scholar 

  166. Lombroso CT. Lamotrigine-induced tourettism. Neurology 1999; 52: 1191–4

    Article  PubMed  CAS  Google Scholar 

  167. Sotero de Menezes MA, Rho JM, Murphy P, et al. Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia 2000; 41: 862–7

    Article  Google Scholar 

  168. Chappel PB, Scahill LD, Leckman JF. Future treatments of Tourette’s syndrome. Neurol Clin 1997; 15: 924–50

    Article  Google Scholar 

  169. Muller N, Riedel M, Erfurth A, et al. Immunoglobulintherapie bei Gilles de la Tourette syndrom. Nervenarzt 1997; 68: 914–6

    Article  PubMed  CAS  Google Scholar 

  170. Perlmutter SJ, Leitman SF, Garvey MA, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999; 354: 1153–8

    Article  PubMed  CAS  Google Scholar 

  171. Leonard HL, Swedo SE, Rapoport JL, et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents: a double-blind crossover comparison. Arch Gen Psychiatry 1989; 46: 1088–92

    Article  PubMed  CAS  Google Scholar 

  172. Yaryura-Tobias JA. Chlorimipramine in Gilles de la Tourette’s disease [letter]. Am J Psychiatry 1975; 132: 1221

    PubMed  CAS  Google Scholar 

  173. Caine ED, Polinsky RJ, Ebert MH, et al. Trial of chlorimipramine and desipramine for Gilles de la Tourette syndrome. Ann Neurol 1979; 5: 305–6

    Article  PubMed  CAS  Google Scholar 

  174. Moshe K, Iulian I, Seth K, et al. Clomipramine-induced tourettism in obsessive-compulsive disorder: clinical and theoretical implications. Clin Neuropharmacol 1994; 17: 338–43

    Article  PubMed  CAS  Google Scholar 

  175. Riddle MA, Leckman JF, Hardin MT, et al. Fluoxetine treatment of obsessions and compulsions in patients with Tourette’s syndrome. Am J Psychiatry 1988; 145: 1173–4

    PubMed  CAS  Google Scholar 

  176. Riddle MA, Hardin MT, King R, et al. Fluoxetine treatment of children and adolescents with Tourette’s and obsessive compulsive disorders: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1990; 29: 45–8

    Article  PubMed  CAS  Google Scholar 

  177. Como PG, Kurlan R. An open-label trial of fluoxetine for obsessive-compulsive disorder in Gilles de la Tourette syndrome. Neurology 1991; 41: 872–4

    Article  PubMed  CAS  Google Scholar 

  178. Kurlan R, Como PG, Deeley C, et al. A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette’s syndrome. Clin Neuropharmacol 1993; 16: 167–72

    Article  PubMed  CAS  Google Scholar 

  179. Eapen V, Trimble MR, Robertson MM. The use of fluoxetine in Gilles de la Tourette syndrome and obsessive compulsive behaviours: preliminary clinical experience. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 737–43

    Article  PubMed  CAS  Google Scholar 

  180. Scahill L, Riddle MA, King RA, et al. Fluoxetine has no marked effect on tic symptoms in patients with Tourette’s syndrome: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1997; 7: 75–85

    Article  PubMed  CAS  Google Scholar 

  181. McDougle CJ, Goodman WK, Leckman JF, et al. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol 1993; 13: 354–8

    Article  PubMed  CAS  Google Scholar 

  182. Bajo S, Battaglia M, Pegna C, et al. Citalopram and fluvoxamine in Tourette’s disorder [letter]. J Am Acad Child Adolesc Psychiatry 1999; 38: 230–1

    Article  PubMed  CAS  Google Scholar 

  183. Ruth U, Mayer-Rosa J, Schlamp D, et al. Tourette-syndrom und antidepressiva-therapie: exazerbation einer ticstorng unter paroxetin. Z Kinder Jugendpsychiatr Psychother 2000; 28: 105–8

    Article  PubMed  CAS  Google Scholar 

  184. Hauser RA, Zesiewicz TA. Sertraline-induced exacerbation of tics in Tourette’s syndrome [letter]. Mov Disord 1995; 10: 682–4

    Article  PubMed  CAS  Google Scholar 

  185. Fennig S. Fennig SN, Pato M, et al. Emergence of symptoms of Tourette’s syndrome during fluvoxamine treatment of obsessive-compulsive disorder. Br J Psychiatry 1994; 164:839–41

    Article  PubMed  CAS  Google Scholar 

  186. Delgado PL, Goodman WK, Price LH, et al. Fluvoxamine/pimozide treatment of concurrent Tourette’s and obsessive-compulsive disorder. Br J Psychiatry 1990; 157: 762–5

    Article  PubMed  CAS  Google Scholar 

  187. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind placebo-controlled study in patients with and withour tics. Arch Gen Psychiatry 1994; 51: 302–8

    Article  PubMed  CAS  Google Scholar 

  188. Sandyk R. Naltrexone suppresses abnormal sexual behavior in Tourette’s syndrome. Int J Neurosci 1988; 43: 107–10

    Article  PubMed  CAS  Google Scholar 

  189. Sandyk R. Naloxone abolishes obsessive-compulsive behavior in Tourette’s syndrome [letter]. Int J Neurosci 1987; 35: 93–4

    Article  PubMed  CAS  Google Scholar 

  190. Denckla MB, Bemporad JR, MacKay MC. Tics following methylphenidate administration. Areport of 20 cases. JAMA 1976; 235: 1349–51

    Article  PubMed  CAS  Google Scholar 

  191. Fras I, Karvalage J. The use of methylphenidate and imipramine in Gilles de la Tourette’s disease in children. Am J Psychiatry 1977; 134: 195–7

    PubMed  CAS  Google Scholar 

  192. Golden GS. The effect of central nervous system stimulants on Tourette syndrome [abstract]. Ann Neurol 1977; 2: 69–70

    Article  PubMed  CAS  Google Scholar 

  193. Pollack MA, Cohen NL, Friedhoff AJ. Gilles de la Tourette’s syndrome. Familial occurrence and precipitation by methylphenidate therapy. Arch Neurol 1977; 34: 630–2

    Article  PubMed  CAS  Google Scholar 

  194. Bremness AB, Sverd J. Methylphenidate-induced Tourette’s syndrome: case report [letter]. Am J Psychiatry 1979; 136: 1334–5

    PubMed  CAS  Google Scholar 

  195. Sleator EK. Deleterious effect of drugs used for hyperactivity on patients with Gilles de la Tourette syndrome [letter]. Clin Pediatr (Phila) 1980; 19: 453–4

    Article  CAS  Google Scholar 

  196. Lowe TL, Cohen DJ, Detlor J, et al. Stimulant medications precipitate Tourette’s syndrome [letter]. JAMA 1982; 247: 1168–9

    Article  PubMed  CAS  Google Scholar 

  197. Lowe TL Cohen DJ, Detlor J, et al. Stimulant medications precipitate Tourette’s syndrome. JAMA 1982; 247: 1729–31

    Article  PubMed  CAS  Google Scholar 

  198. Erenberg G, Cruse RP, Rothner AD. Gilles de la Tourette’s syndrome: effects of stimulant drugs. Neurology 1985; 35: 1346–8

    Article  PubMed  CAS  Google Scholar 

  199. Sverd J, Gadow KD, Paolicelli LM. Methylphenidate treatment of attention-deficit hyperactivity disorder in boys with Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 1989; 28: 574–9

    Article  PubMed  CAS  Google Scholar 

  200. Gadow KD, Nolan EE, Sverd J. Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short-term behavioural effects in school settings. J Am Acad Child Adolesc Psychiatry 1992; 31: 462–71

    Article  PubMed  CAS  Google Scholar 

  201. Lipkin PH, Goldstein IJ, Adesman AR. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med 1994; 148: 859–61

    Article  PubMed  CAS  Google Scholar 

  202. Gadow KD, Nolan E, Sprafkin J, et al. School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. J Dev Behav Pediatr 1995; 16: 167–76

    Article  PubMed  CAS  Google Scholar 

  203. Castellanos FX. Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 1997; 36: 589–96

    Article  PubMed  CAS  Google Scholar 

  204. Castellanos FX. Stimulants and tic disorders: from dogma to data. Arch Gen Psychiatry 1999; 56: 337–8

    Article  PubMed  CAS  Google Scholar 

  205. Law SF, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?. J Am Acad Child Adolesc Psychiatry 1999; 38: 944–51

    Article  PubMed  CAS  Google Scholar 

  206. Freeman RD. Attention deficit hyperactivity disorder in the presence of Tourette’s syndrome. Neurol Clin 1997; 15: 411–20

    Article  PubMed  CAS  Google Scholar 

  207. Steingard R, Biederman J, Spencer T, et al. Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 1993; 32: 350–3

    Article  PubMed  CAS  Google Scholar 

  208. Singer HS, Brown J, Quaskey S, et al. The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995; 95: 74–81

    PubMed  CAS  Google Scholar 

  209. Hoge SK, Biederman J. A case of Tourette’s syndrome with symptoms of attention deficit disorder treated with desipramine. J Clin Psychiatry 1986; 47: 478–9

    PubMed  CAS  Google Scholar 

  210. Sandyk R, Bamford CR. Beneficial effects of imipramine on Tourette’s syndrome. Int J Neurosci 1988; 39: 27–9

    Article  PubMed  CAS  Google Scholar 

  211. Spencer T, Biederman J, Wilens T, et al. Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 1993; 32: 205–10

    Article  PubMed  CAS  Google Scholar 

  212. Frankenburg FR, Kando JC. Sertraline treatment of attention deficity hyperactivity disorder and Tourette’s syndrome [letter]. J Clin Psychopharmacol 1994; 14: 359–60

    Article  PubMed  CAS  Google Scholar 

  213. Culbertson FM. A four-step hypnotherapy model for Gilles de la Tourette’s syndrome. Am J Clin Hypn 1989; 31: 252–6

    Article  PubMed  CAS  Google Scholar 

  214. O’Connor K, Gareau D, Borgeat F. Muscle control in chronic tic disorders. Biofeedback Self Regul 1995; 20: 111–22

    Article  PubMed  Google Scholar 

  215. Peterson AL, Azrin NH. An evaluation of behavioral treatments for Tourette syndrome. Behav Res Ther 1992; 30: 167–74

    Article  PubMed  CAS  Google Scholar 

  216. Carr JE, Bailey JS. A brief behavior therapy protocol for Tourette syndrome. J Behav Ther Exp Psychiatry 1996; 27: 33–40

    Article  PubMed  CAS  Google Scholar 

  217. Michultka DM, Blanchard EB, Rosenblum EL. Stress management and Gilles de la Tourette’s syndrome. Biofeedback Self Regul 1989; 14: 115–23

    Article  PubMed  CAS  Google Scholar 

  218. Bergin A, Waranch HR, Brown J, et al. Relaxation therapy in Tourette’s syndrome: a pilot study. Pediatr Neurol 1998; 18: 136–42

    Article  PubMed  CAS  Google Scholar 

  219. Woods DW, Miltenberger RG, Lumley VA. Sequential application of major habit-reversal components to treat motor tics in children. J Appl Behav Anal 1996; 29: 483–93

    Article  PubMed  CAS  Google Scholar 

  220. Wageman JR, Miltenberger RG, Williams DE. Treatment of a vocal tic by differential reinforcement. J Behav Ther Exp Psychiatry 1995; 26: 35–9

    Article  Google Scholar 

  221. Carr JE. Competing responses for the treatment of Tourette syndrome and tic disorders. Behav Res Ther 1995; 33: 455–6

    Article  PubMed  CAS  Google Scholar 

  222. Swerdlow NR, Gierz M, Berkowitz A, et al. Electroconvulsive therapy in a patient with severe tic and major depressive episode. J Clin Psychiatry 1990; 51: 34–5

    PubMed  CAS  Google Scholar 

  223. Rapoport M, Feder V, Sandor P. Response of major depression and Tourette’s syndrome to ECT: a case report. Psychosom Med 1998; 60: 528–9

    PubMed  CAS  Google Scholar 

  224. Wu L, Li H, Kang L. 156 cases of Gilles de la Tourette’s syndrome treated by acupuncture. J Tradit Chin Med 1996; 16: 211–3

    PubMed  CAS  Google Scholar 

  225. Rauch SL, Baer L, Cosgrove GR, et al. Neurosurgical treatment of Tourette’s syndrome: a critical review. Compr Psychiatr 1995; 36: 141–56

    Article  CAS  Google Scholar 

  226. Leckman JF, de Lotbiniere AJ, Marek K, et al. Severe disturbances in speech, swallowing, and gait following stereotactic infrathalamic lesions in Gilles de la Tourette’s syndrome. Neurology 1993; 43: 890–4

    Article  PubMed  CAS  Google Scholar 

  227. Kurlan R, Kersun J, Ballentine Jr HT, et al. Neurosurgical treatment of severe obsessive-compulsive disorder associated with Tourette’s syndrome. Mov Disord 1990; 5: 152–5

    Article  PubMed  CAS  Google Scholar 

  228. Robertson M, Doran M, Trimble M, et al. The treatment of Gilles de la Tourette’s syndrome by limbic leucotomy. J Neurol Neurosurg Psychiatry 1990; 53: 691–4

    Article  PubMed  CAS  Google Scholar 

  229. Kulisevsky J, Berthier ML, Avila A. Longitudinal evolution of prefrontal leucotomy in Tourette’s syndrome. Mov Disord 1995; 10: 345–8

    Article  PubMed  CAS  Google Scholar 

  230. Vandewalle V, van der Linden Chr, Groenewegen HJ, et al. Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of the thalamus [letter]. Lancet 1999; 353: 724

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Félix Javier Jiménez-Jiménez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jiménez-Jiménez, F.J., García-Ruiz, P.J. Pharmacological Options for the Treatment of Tourette’s Disorder. Drugs 61, 2207–2220 (2001). https://doi.org/10.2165/00003495-200161150-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161150-00005

Keywords

Navigation